PriceTargets.com logo

NASDAQ:INFI - Infinity Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.63
  • Forecasted Upside: 163.70 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$3.65 As of 09/27/2021 01:00 AM ET
▲ +0.1 (2.82%)

This chart shows the closing price for INFI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Infinity Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INFI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INFI

Analyst Price Target is $9.63
▲ +163.70% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Infinity Pharmaceuticals in the last 3 months. The average price target is $9.63, with a high forecast of $14.00 and a low forecast of $4.00. The average price target represents a 163.70% upside from the last price of $3.65.

This chart shows the closing price for INFI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Infinity Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/2/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$6.00High
7/28/2021B. RileyLower Price TargetBuy$7.00 ➝ $4.00High
7/28/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$4.00 ➝ $14.00High
7/27/2021Piper SandlerReiterated RatingOverweight$7.00 ➝ $8.00High
7/7/2021B. RileyReiterated RatingBuy$7.00High
3/23/2021B. RileyLower Price TargetBuy$8.00 ➝ $7.00Low
3/18/2021Truist FinancialInitiated CoverageBuy$12.00High
3/18/2021Truist SecuritiesInitiated CoverageBuy$12.00High
3/18/2021TruistInitiated CoverageBuy$12.00High
3/17/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$2.00 ➝ $4.00High
2/25/2021Piper SandlerInitiated CoverageOverweight$7.00Medium
2/18/2021Piper SandlerInitiated CoverageOverweight$7.00 ➝ $7.00Low
2/12/2021B. RileyBoost Price TargetBuy$4.50 ➝ $8.00Low
2/11/2021OppenheimerBoost Price TargetOutperform$5.50 ➝ $9.00Low
2/5/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralMedium
12/11/2020B. RileyBoost Price TargetBuy$3.00 ➝ $4.50High
11/13/2020B. RileyBoost Price TargetBuy$2.50 ➝ $3.00High
7/31/2020OppenheimerReiterated RatingBuyHigh
5/18/2020B. RileyLower Price TargetBuy$3.50 ➝ $2.50Low
5/12/2020Wells Fargo & CompanyLower Price TargetEqual Weight$1.50 ➝ $1.00High
5/11/2020OppenheimerReiterated RatingBuy$3.00High
3/4/2020Wells Fargo & CompanyLower Price TargetEqual Weight$2.50 ➝ $1.50Medium
11/18/2019B. RileyInitiated CoverageBuy$3.50High
6/27/2019CIBCInitiated CoverageOutperform ➝ OutperformLow
6/27/2019OppenheimerInitiated CoverageOutperform$3.00Medium
1/7/2019UBS GroupReiterated RatingReduceHigh
1/4/2019B. RileyInitiated CoverageBuy ➝ Buy$3.00 ➝ $3.00High
11/12/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformHigh
11/12/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
5/31/2018Seaport Global SecuritiesInitiated CoverageBuy$4.00Medium
10/12/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
11/10/2016JPMorgan Chase & Co.Reiterated RatingHoldN/A
(Data available from 9/27/2016 forward)

News Sentiment Rating

-0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/1/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
Mentions as of
7/29/2021
  • 4 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
8/28/2021
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/27/2021

Current Sentiment

  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Infinity Pharmaceuticals logo
Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $3.65
Low: $3.47
High: $3.77

50 Day Range

MA: $3.15
Low: $1.52
High: $3.82

52 Week Range

Now: $3.65
Low: $1.04
High: $5.98

Volume

1,925,830 shs

Average Volume

4,387,979 shs

Market Capitalization

$323.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Infinity Pharmaceuticals?

The following equities research analysts have issued research reports on Infinity Pharmaceuticals in the last twelve months: B. Riley, JPMorgan Chase & Co., Oppenheimer Holdings Inc., Piper Sandler, Truist, Truist Financial Co., Truist Securities, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for INFI.

What is the current price target for Infinity Pharmaceuticals?

8 Wall Street analysts have set twelve-month price targets for Infinity Pharmaceuticals in the last year. Their average twelve-month price target is $9.63, suggesting a possible upside of 163.7%. Wells Fargo & Company has the highest price target set, predicting INFI will reach $14.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $4.00 for Infinity Pharmaceuticals in the next year.
View the latest price targets for INFI.

What is the current consensus analyst rating for Infinity Pharmaceuticals?

Infinity Pharmaceuticals currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INFI will outperform the market and that investors should add to their positions of Infinity Pharmaceuticals.
View the latest ratings for INFI.

What other companies compete with Infinity Pharmaceuticals?

Other companies that are similar to Infinity Pharmaceuticals include Amgen, Gilead Sciences, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Biogen, Seagen, Alnylam Pharmaceuticals, Novavax, Repligen, Exact Sciences, Incyte, BioMarin Pharmaceutical, Neurocrine Biosciences, United Therapeutics and Exelixis.

How do I contact Infinity Pharmaceuticals' investor relations team?

Infinity Pharmaceuticals' physical mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The biotechnology company's listed phone number is (617) 453-1000 and its investor relations email address is [email protected] The official website for Infinity Pharmaceuticals is www.infi.com.